MIRA Pharmaceuticals Inc is not a strong buy for a beginner, long-term investor at this time. The technical indicators show a bearish trend, there are no positive trading signals, and the financial performance is weak with no revenue and significant losses. Additionally, there are no recent news catalysts or positive sentiment from hedge funds, insiders, or Congress trading data to support a buy decision.
The technical indicators suggest a bearish trend. The MACD is below 0 and negatively contracting, the RSI is neutral at 44.145, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below its pivot level of 1.08, with key support at 0.95 and resistance at 1.21.
NULL identified. No recent news, no positive trading sentiment from hedge funds or insiders, and no Congress trading data.
Bearish technical indicators, weak financial performance with no revenue and significant losses, and no recent positive news or trading sentiment.
In Q3 2025, the company reported no revenue growth (0% YoY), a net income of -22,694,494 (up 1010.37% YoY), and an EPS of -1.18 (up 742.86% YoY). Despite the improvement in net income and EPS, the company remains unprofitable with no revenue.
No analyst rating or price target data is available for MIRA Pharmaceuticals Inc.
